2-羟基植烷酸 | 14721-68-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 2-羟基植烷酸
• 英文名称: 2-Hydroxyphytanic acid
• 英文别名: 2-hydroxy-3,7,11,15-tetramethylhexadecanoic acid
• CAS: 14721-68-7
• 化学式: C₂₀H₄₀O₃
• 分子量: 328.5
• InChiKey: CGKMKXBKVBXUGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090

文献信息

• Novel Carboxylic Acid Derivatives
  申请人：Beumer Raphael

  公开号：US20090258887A1

  公开（公告）日：2009-10-15

  The present invention is concerned with novel arylalkyl carboxylic acid derivatives, more specifically, with acylates of arylalkyl carboxylic acids with naturally occurring, non-toxic hydroxy, sulfhydryl, amino or imino compounds, and to compositions containing them. The compositions are preferably cosmetic preparations.

  本发明涉及一种新颖的芳基烷基羧酸衍生物，更具体地说，涉及芳基烷基羧酸的酰化物与天然存在的、无毒的羟基、硫醇、氨基或亚氨基化合物的组合物，以及含有它们的组合物。这些组合物最好是化妆品制剂。
• Use of phytanic acid for the treatment of diabetes
  申请人：Roche Vitamins AG

  公开号：EP1177789A2

  公开（公告）日：2002-02-06

  This invention relates to a novel method for the treatment or prevention of preferably non-insulin dependent (NIDDM or so-called Type II) diabetes mellitus, or other conditions associated with impaired glucose tolerance such as obesity, and in particular to the use of phytanic acid derivatives for the said treatment or prevention.

  本发明涉及一种治疗或预防非胰岛素依赖型（NIDDM 或所谓的 II 型）糖尿病或其他与葡萄糖耐量受损相关的疾病（如肥胖症）的新方法，尤其涉及使用植烷酸衍生物进行上述治疗或预防。
• CATALASE INHIBITOR AND METHOD FOR MEASURING ANALYTE USING CATALASE INHIBITOR
  申请人：PHC Holdings Corporation

  公开号：EP3473715A1

  公开（公告）日：2019-04-24

  Provided is a catalase inhibitor comprising a compound represented by formula (I): wherein R1 to R4 independently represent a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a carbonyl group,or a hydrocarbon group having 1 to 4 carbon atoms, wherein the hydrocarbon group may have at least one substituent selected from the group consisting of a halogen atom, an amino group, a hydroxyl group and a carbonyl group; and X- represents an anionic chemical species.

  所提供的过氧化氢酶抑制剂由式 (I) 所代表的化合物组成： 其中 R1 至 R4 分别代表氢原子、卤素原子、氨基、羟基、羰基或具有 1 至 4 个碳原子的烃基，其中烃基可具有至少一个选自卤素原子、氨基、羟基和羰基的取代基；以及 X- 代表阴离子化学物质。
• Catalase inhibitor and method for measuring analyte using catalase inhibitor
  申请人：PHC Holdings Corporation

  公开号：US10702503B2

  公开（公告）日：2020-07-07

  Provided is a catalase inhibitor comprising a compound represented by formula (I): wherein R1 to R4 independently represent a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a carbonyl group, or a hydrocarbon group having 1 to 4 carbon atoms, wherein the hydrocarbon group may have at least one substituent selected from the group consisting of a halogen atom, an amino group, a hydroxyl group and a carbonyl group; and X− represents an anionic chemical species.

  所提供的过氧化氢酶抑制剂由式 (I) 所代表的化合物组成： 其中 R1 至 R4 分别代表氢原子、卤素原子、氨基、羟基、羰基或具有 1 至 4 个碳原子的烃基，其中烃基可具有至少一个选自卤素原子、氨基、羟基和羰基的取代基；以及 X- 代表阴离子化学物质。
• In vitro glycosylation of proteins and enzymes
  申请人：Design-Zyme LLC

  公开号：US11021730B2

  公开（公告）日：2021-06-01

  The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least about 7500 Daltons. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.

  本发明广泛涉及新的体外糖基化方法，该方法提供了生产糖基化蛋白质的合理方法，以及糖基化蛋白质的用途。更详细地说，本发明包括对具有亲核分子氨基侧链的起始蛋白质进行糖基化的方法，包括使蛋白质与还原端具有噁唑啉分子的碳水化合物反应，使起始蛋白质的氨基侧链与噁唑啉分子共价键合，其中糖基化的蛋白质基本上保留了起始蛋白质的结构和功能。目标蛋白质包括氧化酶、氧化还原酶和脱氢酶。糖基化蛋白质的分子量至少约为 7500 道尔顿。在另一个实施方案中，本发明涉及糖基化蛋白质在安培生物传感器组装中的使用，糖基化蛋白质是通过本文公开的方法制造的。